Abstract:OBJECTIVETo investigate the clinical benefits and the impacts on distribution and antibiotic resistance of pathogenic bacterium associated with fluoroquinolone prophylaxis during neutropenia in patients with acute leukemia.METHODSA total of 309 infection episodes occurred in patients with acute leukemia were retrospectively analyzed. The patients admitted in ward A (group A, n = 149) received oral ofloxacin as antibacterial prophylaxis during the neutropenia phase; no antibacterial prophylaxis was administered to the patients in ward B (group B, n = 160). The influences of prophylactic ofloxacin were determined by comparative evaluation on the clinical characteristics and the microbiological profile in both groups' patients.RESULTSAlmost all enrolled patients experienced severe neutropenia. The median durations of ANC (absolute neutrophil count, ANC) < 0.2 x 10(9)/L were 11 (range 0 - 43) days. The median persistence time of fever was 8(range 1 - 46) days. Prophylaxis of ofloxacin decreased the proportion of normal flora (P = 0.00). The frequency of Escherichia coli was higher in group A than group B (23.9%, 12.5%, respectively, P = 0.00). Exposure to ofloxacin didn't affect the distributions of other pathogenic bacteria. No difference in the rate of ESBL (+) Escherichia coli was discovered between ofloxacin and no ofloxacin prophylaxis groups (31.9%, 35.4%, respectively, P = 0.61). Commonly used antibiotics had similar activity against the major strains isolated from two groups. Patients who received antibacterial prophylaxis showed a lower incidence (10.7%) of upper respiratory infections/tonsillitis and a relative higher incidence (14.4%) of gastrointestinal tract infections than those without intervention measure. The prophylactic use of ofloxacin couldn't cut down the risk of septicemia. Ofloxacin prophylaxis did not display negative effect on initial clinical response (65.8% in group A, 60.6% in group B, respectively, P = 0.35) and final efficacy (96.0% in group A, 91.9% in group A, P = 0.14) to the same empirical antimicrobial treatment schemes.CONCLUSIONThe fluoroquinolone prophylaxis induces diminishing proportion of normal flora and increasing frequency of Escherichia coli in severely neutropenic patients with acute leukemia, may not influence the distribution of other bacteria. The susceptibility of main pathogens may not be affected by antibiotic prophylaxis. The fluoroquinolone don't decrease the incidence of septicemia and infection in gastrointestinal tract. Our data suggest that more prudent use of antibiotic prophylaxis may be reasonable even in patients at high-risk for developing infection.

Clinical analysis of fluoroquinolone-induced acute interstitial nephritis

Nephrotoxicity of fluoroquinolones:a review.

Adverse Drug Reactions Induced by Gatifloxacin:Analysis of 866 Cases During 2003～2006

The Influence of Influenza A (h1n1) Virus on Creatinine and Cystatin C

A Phase Ii Study of Antofloxacin Hydrochloride, A Novel Fluoroquinolone, for the Treatment of Acute Bacterial Infections

Acute ciprofloxacin-induced crystal nephropathy with granulomatous interstitial nephritis

[Clinical Study on Fluoroquinolone Prophylaxis in Neutropenia Patients with Acute Leukemia].

Clinical evaluation on the empirical treatment of community acquired pneumonia

Safety Profile of Fluoroquinolones: Analysis of Adverse Drug Reactions in Relation to Consumption Data Using Pharmacovigilance Database in Hebei, China

Ciprofloxacin crystal nephropathy

Clinical efficacy of ofloxacin and levofloxacin treatment on pelvic inflammatory disease

Association between initiation of fluoroquinolones and hospital admission or emergency department visit for suicidality: population based cohort study

Clinicopathological Analysis on Glomerulonephritis Complicating with Acute Interstitial Nephritis

Significance of acute kidney injury biomarkers in the treatment of refractory nephrotic syndrome with calcineurin inhibitors

The clinical analysis of 81 cases with drug-induced acute renal failure

Drug-induced acute kidney injury: a clinical and pathological analysis

Analysis of drug-induced acute renal failure in Shanghai

Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial

Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database

Clinical evaluation of pazufloxacin and levofloxacin in the treatment of bacterial infections

Clinical Characteristics of Patients with Acyclovir-induced Acute Renal Failure：Case Report